title: Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells.
abstract: Niacin is a widely used lipid-regulating agent in dyslipidemic patients. Previously, we have shown that niacin inhibits triacylglycerol synthesis. In this report, using HepG2 cells, we have examined the effect of niacin on the mRNA expression and microsomal activity of diacylglycerol acyltransferase 1 and 2 (DGAT1 and DGAT2), the last committed but distinctly different enzymes for triglyceride synthesis. Addition of niacin to the DGAT assay reaction mixture dose-dependently (0-3 mM) inhibited DGAT activity by 35-50%, and the IC(50) was found to be 0.1 mM. Enzyme kinetic studies showed apparent K(m) values of 8.3 microM and 100 microM using [(14)C]oleoyl-CoA and sn-1,2-dioleoylglycerol as substrates, respectively. A decrease in apparent V(max) was observed with niacin, whereas the apparent K(m) remained constant. A Lineweaver-Burk plot of DGAT inhibition by niacin showed a noncompetitive type of inhibition. Niacin selectively inhibited DGAT2 but not DGAT1 activity. Niacin inhibited overt DGAT activity. Niacin had no effect on the expression of DGAT1 and DGAT2 mRNA. These data suggest that niacin directly and noncompetitively inhibits DGAT2 but not DGAT1, resulting in decreased triglyceride synthesis and hepatic atherogenic lipoprotein secretion, thus indicating a major target site for its mechanism of action.
authors.affiliation: Atherosclerosis Research Center, Department of Veterans Affairs Healthcare System, Long Beach, CA, USA.
authors.forename: Shobha H
authors.initials: SH
authors.lastname: Ganji
authors.forename: S
authors.initials: S
authors.lastname: Tavintharan
authors.forename: Daming
authors.initials: D
authors.lastname: Zhu
authors.forename: Yiding
authors.initials: Y
authors.lastname: Xing
authors.forename: Vaijinath S
authors.initials: VS
authors.lastname: Kamanna
authors.forename: Moti L
authors.initials: ML
authors.lastname: Kashyap
mesh_terms: D000217:Acyltransferases / Q000037:antagonists & inhibitors* / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D045744:Cell Line, Tumor; D051048:Diacylglycerol O-Acyltransferase; D004305:Dose-Response Relationship, Drug; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects*; D022781:Hepatocytes / Q000378:metabolism*; D006801:Humans; D007700:Kinetics; D008074:Lipoproteins / Q000378:metabolism; D009525:Niacin / Q000494:pharmacology*; D012333:RNA, Messenger / Q000032:analysis; D014280:Triglycerides / Q000096:biosynthesis
chemical_list: D008074:Lipoproteins; D012333:RNA, Messenger; D014280:Triglycerides; D009525:Niacin; D000217:Acyltransferases; C494881:DGAT1 protein, human; C494885:DGAT2 protein, human; D051048:Diacylglycerol O-Acyltransferase